GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (FRA:GKO) » Definitions » Shiller PE Ratio

GlycoMimetics (FRA:GKO) Shiller PE Ratio : (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GlycoMimetics Shiller PE Ratio Historical Data

The historical data trend for GlycoMimetics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics Shiller PE Ratio Chart

GlycoMimetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlycoMimetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlycoMimetics's Shiller PE Ratio

For the Biotechnology subindustry, GlycoMimetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoMimetics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Shiller PE Ratio falls into.



GlycoMimetics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GlycoMimetics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, GlycoMimetics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.156/129.4194*129.4194
=-0.156

Current CPI (Mar. 2024) = 129.4194.

GlycoMimetics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.287 100.560 0.369
201409 -0.272 100.428 -0.351
201412 -0.316 99.070 -0.413
201503 -0.342 99.621 -0.444
201506 0.454 100.684 0.584
201509 -0.339 100.392 -0.437
201512 -0.431 99.792 -0.559
201603 -0.359 100.470 -0.462
201606 -0.365 101.688 -0.465
201609 -0.303 101.861 -0.385
201612 -0.341 101.863 -0.433
201703 -0.318 102.862 -0.400
201706 -0.267 103.349 -0.334
201709 -0.201 104.136 -0.250
201712 -0.228 104.011 -0.284
201803 -0.268 105.290 -0.329
201806 -0.223 106.317 -0.271
201809 -0.231 106.507 -0.281
201812 -0.281 105.998 -0.343
201903 -0.292 107.251 -0.352
201906 -0.327 108.070 -0.392
201909 -0.281 108.329 -0.336
201912 -0.306 108.420 -0.365
202003 -0.163 108.902 -0.194
202006 -0.284 108.767 -0.338
202009 -0.246 109.815 -0.290
202012 -0.263 109.897 -0.310
202103 -0.235 111.754 -0.272
202106 -0.232 114.631 -0.262
202109 -0.289 115.734 -0.323
202112 -0.292 117.630 -0.321
202203 -0.254 121.301 -0.271
202206 -0.237 125.017 -0.245
202209 -0.162 125.227 -0.167
202212 -0.179 125.222 -0.185
202303 -0.159 127.348 -0.162
202306 -0.120 128.729 -0.121
202309 -0.131 129.860 -0.131
202312 -0.128 129.419 -0.128
202403 -0.156 129.419 -0.156

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlycoMimetics  (FRA:GKO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


GlycoMimetics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoMimetics (FRA:GKO) Business Description

Traded in Other Exchanges
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.